News | Latest Breaking News Stories & Headlines

Johnson & Johnson faces other legal actions, including an ongoing trial in California

Johnson & Johnson to 'exit' US opioid business

US pharmaceutical giant Johnson & Johnson will "exit from the opioid business nationally" as part of a $230 million settlement with New York, the state's attorney general Letitia James said Saturday.

US • 26 Jun 21

Use of the company's one-dose vaccine was temporarily halted by US regulators last week

EMA: Benefits of J&J Covid-19 vaccine outweigh risks

The European Medicines Agency has said the benefits of the Johnson & Johnson Covid-19 vaccine outweigh the risks.

Coronavirus • 20 Apr 21

Johnson & Johnson said the Covid-19 vaccine will be available on a not-for-profit basis until the end of the pandemic

J&J reports $100m in vaccine sales in first quarter

Johnson & Johnson has today beaten expectations for quarterly revenue and profit and raised dividend payouts to shareholders.

Business • 20 Apr 21

Vials of the Janssen vaccine from Johnson & Johnson

Johnson & Johnson delays European vaccine roll-out

Johnson & Johnson has said it will delay the roll-out of its Covid-19 vaccine in Europe after US authorities moved to suspend use of the shot due to health concerns.

Coronavirus • 13 Apr 21

The European Medicines Agency is reviewing reports of thromboembolic events with people who received a J&J jab

EMA to review blood clot link with J&J Covid-19 vaccine

The EU's drug regulator has said it has launched a review of possible links between the Johnson & Johnson coronavirus vaccine and blood clots after reports of four cases, one of them fatal.

Coronavirus • 09 Apr 21

Ireland is set to receive 2.2 million doses of the vaccine

J&J to deliver Covid-19 vaccine to Europe from 19 April

Johnson & Johnson has said it would start delivering its single-shot Covid-19 vaccine to Europe on 19 April, giving the continent a boost as it struggles to speed up its vaccination drive.

Coronavirus • 29 Mar 21

It is the fourth vaccine against the coronavirus approved for use in Europe

One-shot J&J vaccine approved by EU drugs regulator

The European Union's drugs regulator has recommended conditionally approving Johnson & Johnson's single dose Covid-19 vaccine.

Coronavirus • 11 Mar 21

Johnson & Johnson's one shot jab is the third vaccine the US is licensing to fight the Coronavirus pandemic

US to approve Johnson & Johnson Covid vaccine

A US panel of independent experts has voted unanimously in favour of recommending Johnson & Johnson's one-dose Covid-19 shot for emergency approval.

Coronavirus • 27 Feb 21

J&J said it was expecting data sometime next week and was optimistic that it would be robust

Johnson & Johnson promises 2021 profit jump

Johnson & Johnson has today forecast 2021 profit above Wall Street estimates and promised data from its widely watched coronavirus vaccine trial soon.

Business • 26 Jan 21

The Johnson & Johnson Phase 3 trial had started recruiting participants in late September

Johnson & Johnson pauses Covid vaccine trial

Johnson & Johnson has temporarily halted its Covid-19 vaccine trial because one of its participants had become sick, the company said.

Coronavirus • 13 Oct 20

The deal gives J&J's Janssen unit access to Momenta's experimental therapy, nipocalimab

J&J in deal for autoimmune disease specialist Moment

Johnson & Johnson has today agreed to pay about $6.5 billion in cash to buy Momenta Pharmaceuticals in a deal aimed at expanding its portfolio of autoimmune disease treatments.

Business • 19 Aug 20

Dr Anthony Fauci said it was 'likely' a vaccine would be available early next year

Covid vaccine 'likely' to be available in 2021 - Fauci

Drug companies will likely have tens of millions of doses of coronavirus vaccines in the early part of next year, with production ramping up to a billion doses by the end of 2021.

Coronavirus • 05 Aug 20

The company is the first major drugmaker to report quarterly earnings and its upbeat outlook and results could be a positive sign for the sector

Prescription drugs boosts Johnson & Johnson forecasts

Johnson & Johnson raised its full-year earnings forecast as it reported higher third-quarter sales of psoriasis treatment Stelara and cancer drug Imbruvica while attempting to alleviate investor concerns over mounting legal challenges.

Business • 15 Oct 19

Johnson & Johnson said the award was "grossly disproportionate"

US firm ordered to pay man $8bn over breast growth

A Pennsylvania jury has ruled that US pharmaceutical giant Johnson & Johnson must pay $8 billion in damages and interest for failing to warn that a psychiatric drug could cause breast growth in men.

World • 09 Oct 19

Purdue Pharma has agreed tentative multibillion-dollar deal with some plaintiffs aimed at settling thousands of lawsuits over its alleged role in the US opioid crisis

Purdue deal to rank among biggest in pharma history

OxyContin maker Purdue Pharma LP has reached a tentative multibillion-dollar agreement with some plaintiffs aimed at settling thousands of lawsuits over its alleged role in the US opioid crisis.

Business • 16 Sep 19

J&J's sales increased slightly to $20.02 billion, edging past the average estimate of $19.61 billio

J&J boosted by better than expected pharma unit sales

Johnson & Johnson beat quarterly profit estimates on higher sales at its pharmaceuticals unit even as it faces fierce competition for some of its biggest drugs.

Business • 16 Apr 19

The decline in shares wiped off about $24bn from the company's market capitalisation

J&J shares drop 6% following report over asbestos

Shares of Johnson & Johnson (J&J) fell over 6% after Reuters reported that the pharmaceutical company knew that its baby powder was contaminated with cancer-causing asbestos.

World • 14 Dec 18

J&J says it faces lawsuits by 4,800 plaintiffs nationally asserting similar claims over its talc-based products

Reversal of J&J $72m verdict over talc cancer risks

Johnson & Johnson has won the reversal of a $72m (€61.3m) verdict in the US in favour of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company's talc-based products like Johnson's Baby Powder.

Business • 18 Oct 17

The verdict included $70m in compensatory damages and $347m in punitive damages

J&J ordered to pay $417m in trial over talc cancer risk

A US jury has ordered Johnson & Johnson to pay $417m to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene.

Business • 22 Aug 17

Johnson & Johnson